AstraZeneca’s Farxiga cuts heart risk in type 2 diabetes patients

pharmafile | September 24, 2018 | News story | Research and Development, Sales and Marketing AstraZeneca, diabetes, farxiga, pharma 

AstraZeneca has unveiled new Phase 3 data for its SGLT2 inhibitor Farxiga (dapagliflozin), showing with the drug demonstrating positive findings in the in improving cardiovascular (CV) outcomes vs placebo in patients with type 2 diabetes (T2B) and multiple CV risk factors or established disease.

In the large-scale trial, which was conducted across 33 different countries over five years and involved over 17,000 participants, Farxiga was shown to achieve a “statistically significant reduction” in hospitalisations for heart failure (hHF) or CV death

Additionally, the drug also met its primary safety endpoint of non-inferiority for major adverse cardiovascular events (MACE) and reinforced its “well-established” safety profile.

“Farxiga has achieved a statistically-significant and clinically-important reduction in hospitalisation for heart failure or cardiovascular death in a broad range of patients with type-2 diabetes and cardiovascular risk,” said Elisabeth Björk, Head of Cardiovascular, Renal and Metabolism at AstraZeneca Global Medicines Development. “The results from this landmark trial are especially important since heart failure is an early and frequent complication of diabetes and associated with hospitalisations that result in a considerable societal and economic burden.”

Dr Stephen Wiviott, of Brigham and Women’s Hospital and Harvard Medical School and co-principal investigator of the trial, said that the study presented “compelling evidence” of Farxiga’s ability to effectively address unmet medical need “with a safety profile supportive of broad use.”

The company confirmed that full data from the study would be presented at the American Heart Association Scientific Sessions 2018 on 10 November in Chicago, US.

Matt Fellows

Related Content


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA approves new insulin pump and algorithm software for enhanced automated insulin delivery

The US Food and Drug Administration (FDA) has announced that it has cleared the Beta …

Latest content